Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Tax Provision : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Tax Provision?

Paradigm Biopharmaceuticals's tax provision for the six months ended in Dec. 2023 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Paradigm Biopharmaceuticals Tax Provision Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Tax Provision Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Tax Provision

Get a 7-Day Free Trial

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Tax Provision	Get a 7-Day Free Trial												-	-	-	-	-

Paradigm Biopharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).